CDIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CDIO is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows a slight short-term uptick, but the broader technical trend remains bearish, fundamentals are weakening, and there is no strong proprietary buy signal to support an aggressive entry. For an impatient investor who does not want to wait for a better setup, this still does not justify buying now.
Current price is 1.8, slightly above the previous close of 1.79, with a 5.29% pre-market/regular session change shown in the data. Short-term momentum is mixed: MACD histogram is positive and expanding, which suggests improving near-term momentum, but RSI at 42.31 is neutral and not showing strong buying pressure. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, which indicates the longer-term trend is still weak. Price is below the pivot at 1.881, with resistance at 2.057 and 2.166, and support at 1.706 and 1.597. Overall, the chart does not confirm a durable uptrend yet.
The only clear positive catalyst is the positive MACD expansion, which may hint at short-term momentum building. The stock trend model also suggests a 40% chance of a 5.89% move higher in the next day, which supports a possible short-term bounce.
There was no news in the past week, so no event-driven catalyst is currently supporting the stock. Hedge funds are neutral and insiders are neutral, showing no significant conviction from major holders. The latest quarter financials were weak: revenue fell 21.21% year over year in 2025/Q4, net income remained deeply negative at -1,465,368, and EPS dropped 31.03% year over year. The bearish moving average structure also signals that the broader trend remains under pressure.
In 2025/Q4, Cardio Diagnostics Holdings reported weaker financial performance. Revenue declined to 3,555, down 21.21% year over year, which shows slowing business growth. Net income was -1,465,368, still negative and slightly worse year over year, while EPS fell to -0.8, down 31.03% year over year. Gross margin was reported at 100, but the overall picture remains one of contracting revenue and persistent losses.
No analyst rating or price target change data was provided, so there is no visible Wall Street consensus trend to support a buy case. Based on the available data, Wall Street pros would likely lean cautious: the pro side is a possible short-term momentum bounce, while the con side is declining revenue, losses, neutral insider/hedge fund activity, and no recent news catalyst. Overall, the professional view appears mixed to negative rather than bullish.
